Background: Although intravoxel incoherent motion (IVIM) MRI has emerged as an in vivo marker of tissue diffusion and perfusion, its prognostic value in patients with hypertrophic cardiomyopathy (HCM) remains unclear.

Purpose: To investigate whether IVIM-MRI derived parameters are associated with outcomes in patients with HCM.

Study Type: Prospective cohort.

Subjects: A total of 112 patients (51.72 ± 17.13 years) with suspected or known HCM.

Field Strength/sequence: Single-shot echo planar IVIM imaging, balanced steady-state free precession, and phase-sensitive inversion-recovery late gadolinium enhancement (LGE) sequences at 3 T.

Assessment: All patients were followed up of 29.3 ± 12.3 months for combined major adverse cardiac events (MACE) including cardiac death, aborted sudden death, heart transplantation, and rehospitalization for heart failure. The CVI42 imaging platform was used to assess morphological and functional MRI indices and to quantify LGE. The Body Diffusion Toolbox was used to derive pseudo diffusion (D*), water molecular diffusion (D) and perfusion fraction (f).

Statistical Tests: Univariable and stepwise multivariable Cox model analyses were used to investigate the association between variables and composite endpoints. Kaplan-Meier curves were constructed to assess event-free survival, and the event rates were compared by the log-rank test.

Results: A total of 19 patients reached endpoints. Patients with MACE showed a significantly impaired D* value, lower f value, and more extensive LGE than those without MACE (all, P < 0.05), while there was no significant difference in D value (P = 0.285). In the Cox regression models, D* value (hazard ratio [HR] 0.93; 95% CI: 0.88-0.98) and f value (HR 0.65; 95% CI: 0.45-0.92) were independent predictors for MACE. Moreover, in Kaplan-Meier survival analysis, the incidence of MACE was significantly higher in patients with decreased D* value and f value.

Conclusions: Impaired D* and f values derived from IVIM-MRI are associated with adverse outcomes in patients with HCM.

Level Of Evidence: 2 TECHNICAL EFFICACY STAGE: 2.

Download full-text PDF

Source
http://dx.doi.org/10.1002/jmri.28450DOI Listing

Publication Analysis

Top Keywords

hypertrophic cardiomyopathy
8
intravoxel incoherent
8
incoherent motion
8
diffusion perfusion
8
patients
6
microvascular dysfunction
4
dysfunction associates
4
associates outcomes
4
outcomes hypertrophic
4
cardiomyopathy insights
4

Similar Publications

Background: There is a shortage of patients with hypertrophic cardiomyopathy (HCM) with concurrent coronary artery disease (CAD), and the influence of CAD on the prognosis of patients with HCM is uncertain. This real-world cohort study was conducted to evaluate the prognosis of patients with patients with CAD.

Methods: This cohort study of patients with HCM was conducted from May 2003 to September 2021.

View Article and Find Full Text PDF

Pathogenic genes and clinical prognosis in hypertrophic cardiomyopathy.

World J Cardiol

January 2025

Institute of Cardiovascular Diseases & Department of Cardiology, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610072, Sichuan Province, China.

Hypertrophic cardiomyopathy (HCM) is an autosomal dominant inherited cardiomyopathy characterized by left ventricular hypertrophy. It is one of the chief causes of sudden cardiac death in younger people and athletes. Molecular-genetic studies have confirmed that the vast majority of HCM is caused by mutations in genes encoding sarcomere proteins.

View Article and Find Full Text PDF

Author's Reply to Impact of Mavacamten on Atrial Fibrillation in Patients with Obstructive Hypertrophic Cardiomyopathy.

Heart Rhythm

January 2025

Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA; Department of Molecular Pharmacology & Experimental Therapeutics (Windland Smith Rice Sudden Death Genomics Laboratory). Electronic address:

View Article and Find Full Text PDF

To the Editor-Impact of mavacamten on atrial fibrillation in patients with obstructive hypertrophic cardiomyopathy.

Heart Rhythm

January 2025

Aurora Cardiovascular and Thoracic Services, Aurora Sinai/Aurora St. Luke's Medical Centers, Aurora Health Care, Milwaukee, Wisconsin, USA; Division of Cardiovascular Medicine, University of Wisconsin School of Medicine and Public Health, Milwaukee Clinical Campus, Milwaukee, Wisconsin, USA. Electronic address:

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!